On the horizon: Immunotherapy strategies for relapsed/refractory high-risk neuroblastoma

WELCOME

WELCOME TO THIS WEBCAST

On the horizon: Immunotherapy strategies for relapsed/refractory high-risk neuroblastoma, brought to you by Postgraduate Institute for Medicine and Ology Medical Education, was originally presented as a live virtual, CME-certified 90-minute satellite symposium at the SIOP 2020 Virtual Congress.

A CME-accredited on-demand webcast of the satellite symposium plus downloadable slides and transcript will be available for you, and for you to share with your colleagues, from January 2021 for a period of 1 year.

PROGRAM

Unmet needs in R/R high-risk neuroblastoma: rising to the challenge

Susan Cohn, MD

University of Chicago
Chicago, IL, USA

Targeted antibody-based immunotherapy approaches in the R/R setting: evidence and perspectives

Daniel Morgenstern, MB BChir, PhD

The Hospital for Sick Children and the University of Toronto
Toronto, ON, Canada

Optimizing clinical management and treatment outcomes: a multidisciplinary approach

Jaume Mora, MD, PhD

Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu
Barcelona, Spain

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

Recognize the unmet needs in patients with relapsed/refractory high-risk neuroblastoma
Describe the rationale and role of immunotherapy for the treatment of high-risk neuroblastoma in the relapsed/refractory setting
Evaluate the efficacy and safety profiles of anti-GD2-based immunotherapies
Discuss the integration of current and emerging immunotherapies into conventional multimodality treatment and importance of a multidisciplinary approach to care